EW stock: buy or sell?
October 18th, 2019
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally.
Should I buy EW stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading plan that matches with your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Edwards Lifesciences stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Edwards Lifesciences stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we gathered 15 ratings published for EW stock in the last month. The general sentiment of these ratings is bullish for EW stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-6||Wells Fargo & Co||n/a||Outperform|
|2019-9-23||Piper Jaffray Companies||n/a||Overweight|
|2019-7-24||Wells Fargo & Co||n/a||Outperform|
|2019-7-24||JPMorgan Chase & Co.||n/a||Neutral|
|2019-7-24||Jefferies Financial Group||n/a||Buy|
|2019-7-24||Credit Suisse Group||n/a||Outperform|
|2019-7-24||BMO Capital Markets||n/a||Outperform|
|2019-7-24||Bank of America||Buy||Buy|
EW stock analysis
Edwards Lifesciences stayed steady -0.15% to $227.46 after marking all time highs on October/11.
Edwards Lifesciences stayed constant -0.15% on Oct 18th to $227.46 after marking all time highs on Oct 11th. Since SMA50d and SMA100d crossed up on July, EW price climbed $36.28 per share (18.98%). On Oct 11th, EW hit new all time highs, pushing higher previous ATH of $229.97 recorded on Oct 4th. New ATHs are usual entry points for many trading setups as there aren't higher resistences. Since price and SMA100d lines crossed up on June, EW climbed $53.42 (30.69%).
Edwards Lifesciences shares stayed steady 0.15% this week, ending at $227.46. Late September EW rocketed a cool 5.28% in just one week.
Edwards Lifesciences stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Not so far away is the last all-time high Edwards Lifesciences marked last week. Late December 2018 EW price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
EW stock price history
EW stock went public on March 27th, 2000 with a price of $3.811. Since then, EW stock grew a 5,870.10%, with a yearly average of 309.00%. If you had invested $1,000 in EW stock in 2000, it would worth $58,701.00 today.
1: Adjusted price after possible price splits or reverse-splits.
EW stock historical price chart
EW stock reached all-time highs on October 11th with a price of $230.19.
EW stock price target is $227.30Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 14 price predictions for EW stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-6||Wells Fargo & Co||Raises Target||$220.00||$250.00||13.6%|
|2019-9-23||Piper Jaffray Companies||Initiates||n/a||$240.00||-|
|2019-7-24||Wells Fargo & Co||Reiterates||$207.00||$220.00||6.3%|
|2019-7-24||Raymond James||Raises Target||$200.00||$232.00||16%|
|2019-7-24||Morgan Stanley||Raises Target||$210.00||$228.00||8.6%|
|2019-7-24||JPMorgan Chase & Co.||Raises Target||$190.00||$225.00||18.4%|
|2019-7-24||Jefferies Financial Group||Reiterates||$210.00||$245.00||16.7%|
|2019-7-24||Credit Suisse Group||Reiterates||$221.00||$226.00||2.3%|
|2019-7-24||BMO Capital Markets||Reiterates||$204.00||$224.00||9.8%|
|2019-7-24||Bank of America||Reiterates||$215.00||$225.00||4.7%|
|2019-7-16||Morgan Stanley||Raises Target||$197.00||$210.00||6.6%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on April, Edwards Lifesciences . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Edwards Lifesciences annual turnover rose a great 8.37% to $3,722.80 million dollars from $3,435.30 marked in 2017. In contrast, its profit margin (compared to revenues) inched to 19.40%, that is $722.20 million. To have an updated view of the financial situation of Edwards Lifesciences, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Edwards Lifesciences TTM sales up to March 2019 were $3,821.00 and earnings were $765.30 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Edwards Lifesciences business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, appreciated a tiny 2.64%. Regarding profit margin, Edwards Lifesciences remained stable 0.63% to 19.40%
|2013||$2,050 M||-||$392 M19.1%||-|
|2014||$2,323 M||13.31%||$811 M34.9%||107.07%|
|2015||$2,494 M||7.35%||$495 M19.8%||-38.98%|
|2016||$2,964 M||18.85%||$570 M19.2%||15.07%|
|2017||$3,435 M||15.91%||$584 M17.0%||2.48%|
|2018||$3,723 M||8.37%||$722 M19.4%||23.75%|
|TTM||$3,821 M||2.64%||$765 M20.0%||5.97%|
Quarterly financial resultsEdwards Lifesciences posted $993.00 M in revenues for 2019-Q1, a 1.56% up compared to previous quarter. Reported quarter income marked $249.70 M with a profit margin of 25.15%. Profit margin skyrocketed a 24.43% compared to previous quarter when profit margin was 0.72%. When comparing turnover to same quarter last year, Edwards Lifesciences sales marked a superb increase and rocketed a 10.97%. Looking back to recent quarterly results, Edwards Lifesciences posted 2 negative quarters in a row.
|2017-Q2||$842 M||-||$186 M22.1%||-|
|2017-Q3||$822 M||-2.41%||$170 M20.7%||-8.60%|
|2017-Q4||$889 M||8.16%||$-3 M-0.3%||-101.65%|
|2018-Q1||$895 M||0.71%||$207 M23.1%||-7,478.57%|
|2018-Q2||$944 M||5.46%||$283 M30.0%||36.83%|
|2018-Q3||$907 M||-3.93%||$226 M24.9%||-20.09%|
|2018-Q4||$978 M||7.84%||$7 M0.7%||-96.90%|
|2019-Q1||$993 M||1.56%||$250 M25.1%||3,467.14%|
Edwards Lifesciences ownershipWhen you are planning to buy shares of a company, it's worth to have a look its ownership structure.
Edwards Lifesciences shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 3.94% of all shares.
In case of Edwards Lifesciences stock, 0.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for EW stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Edwards Lifesciences:
|Market cap||$47.3 B||$53.5 B||$888.0 M||$3.2 B||$695.7 M|
|Total shares||208.0 M||1,390.0 M||37.5 M||20.7 M||19.9 M|
|Float shares||206.5 M||1,390.0 M||36.0 M||19.2 M||16.1 M|
|- Institutional holdings (%)||0.0%||93.4%||72.1%||93.5%||77.8%|
|- Insider holdings (%)||3.9%||0.2%||3.8%||7.1%||18.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, October 18th, 2019|
|Day range||$227.29 - $229.67|
|Average true range||$5.17|
|50d mov avg||$220.31|
|100d mov avg||$206.69|
|200d mov avg||$191.04|
Edwards Lifesciences performanceTo better understand Edwards Lifesciences performance you must becnhmark its gains with other related stocks in same sector or industry. For Edwards Lifesciences, the comparison is made against Boston Scientific, CryoLife, ICU Medical, LeMaitre Vascular, Medtronic and Merit Medical Systems.
|MMSIMerit Medical Sys...||-44.31%||-46.86%||-51.15%|
Edwards Lifesciences competitorsWe selected a few stocks to conform a list of Edwards Lifesciences competitors to watch if you are interested in investing in EW:
- Boston Scientific (BSX)
- CryoLife (CRY)
- ICU Medical (ICUI)
- LeMaitre Vascular (LMAT)
- Medtronic (MDT)
- Merit Medical Systems (MMSI)
Latest EW stock news
- Seeking AlphaEdwards Lifesciences Beats, Raises And Surges: AnalysisJuly 24, 2019
- Seeking AlphaEdwards Lifesciences: A Med-Tech Stock Staying Strong For A ReasonMay 15, 2019
- Seeking AlphaEdwards Lifesciences: Assessing The Next MovesMay 1, 2019
- Seeking AlphaEdwards Lifesciences: It's Expensive, But It's Recession-ProofFebruary 20, 2019
- Seeking AlphaEdwards Lifesciences: Good For The Heart And Your PortfolioAugust 17, 2018